One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Anti-Viral Therapeutics Market

[ 英語タイトル ] Anti-Viral Therapeutics Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083722
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - AbbVie Inc.
- Bristol-Meyrs Squibb Company
- Cipla Inc.
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Johnson & Johnson
- Merck & Co. Inc.
- Pfizer Inc.
- Sanofi

[Report Description]

The anti-viral therapeutics market is expected to register a CAGR of 6.0%, over the forecast period. North America dominates the market, owing to the growing prevalence of hepatitis C and human immunodeficiency viruses (HIV) infections, coupled with the presence of a huge patient pool suffering from virally infectious diseases.

- In order to combat drug resistance, the combination of various anti-virals with different mechanisms of action is used. Combination antiviral therapy is the standard of care in HIV and hepatitis C virus infections, and it is likely to become increasingly used in other viral infections.
- Anti-viral therapeutics are commercially available for diseases, like influenza, hepatitis C, chickenpox, papilloma, and AIDS, among others. Additionally, there is increasing adoption of nucleoside and nucleotide analogues as first-line anti-virals. Based on the current development pipeline, many small molecule-based anti-viral drugs (like interferons and other similar small protein analogues) are expected to receive its marketing approval.

Key Market Trends

On the Basis of Drug Type, HIV Antiviral Drugs Mainly Boost the Global Market

HIV is a major global public health issue. According to the 2019 UNAIDS data, 24.5 million people were accessing antiretroviral therapy by the end of 2019. 1.7 million became newly infected with the virus in 2018. The vast majority of people living with HIV are located in low and middle-income countries, with an estimated 66% living in sub-Saharan Africa. However, the majority of HIV anti-viral consumption was exhibited in the North American region. Over the forecast period, the use of anti-virals in African countries is expected to increase multifold, as the majority of global companies are strategizing their HIV based products in the emerging market.

North America Region Expected to Dominate the Market Over the Forecast Period

North America dominated the anti-viral therapeutics market, owing to the presence of well-established market players, and also due to the growing prevalence of HIV and hepatitis C infections. The North American market is primarily driven by factors, such as the increasing occurrence of infectious disease, increasing geriatric population base, and growing healthcare awareness coupled with increasing healthcare expenditure in the region. However, there are limitations to market growth in the region, which include generic erosion and patent expiration of anti-viral drugs.

Competitive Landscape

The anti-viral therapeutics market is a fast-growing market. The current market share is majorly controlled by a few major pharmaceutical and biotechnology companies. There is a limited number of antiviral products in the market, and a large percentage of these drugs are expected to lose exclusivity in the coming future. This will be marked by the entry of generic manufacturers, expansion of market size, and lowering of market concentration.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
4.2.2 Advancements in Molecular Biology Promoting Drug Development
4.2.3 Growing Burden of HIV Infection
4.3 Market Restraints
4.3.1 High Cost of Antiviral Drug Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Drug Type
5.1.1 Herpes Antiviral Drugs
5.1.2 Hepatitis Antiviral Drugs
5.1.3 HIV Antiviral Drugs
5.1.4 Influenza Antiviral Drugs
5.1.5 Others Antiviral Drugs
5.2 By Distribution Channel
5.2.1 Hospital Pharmacy
5.2.2 Independent Pharmacy and Drug Store
5.2.3 Online Pharmacy
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc.
6.1.2 Bristol-Meyrs Squibb Company
6.1.3 Cipla Inc.
6.1.4 F. Hoffmann-La Roche Ltd
6.1.5 Gilead Sciences Inc
6.1.6 GlaxoSmithKline Plc
6.1.7 Johnson & Johnson
6.1.8 Merck & Co. Inc.
6.1.9 Pfizer Inc.
6.1.10 Sanofi




Recommended reports